Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$42.96 USD
-0.79 (-1.81%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $42.94 -0.02 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Kymera Therapeutics, Inc. has a market cap of $2.85B, which represents its share price of $43.75 multiplied by its outstanding shares number of 65.12M. As a mid-cap company, KYMR's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
KYMR 42.96 -0.79(-1.81%)
Will KYMR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KYMR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KYMR
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
KYMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
Other News for KYMR
Kymera Therapeutics (KYMR) Gains Support as Data Release Approaches
Kymera Therapeutics transferred with Buy rating at B. Riley
Goldman Sachs Initiates Coverage on Kymera Therapeutics (KYMR) as Early-Stage Biotech | KYMR ...
Kymera Therapeutics initialed with Early-Stage Biotech at Goldman Sachs
Gilead sees Q2 EPS hit from IPR&D expenses